Mark A. Socinski, MD, AdventHealth Cancer Institute

Articles

Immunotherapy for NSCLC: Clinical Pearls

August 25th 2021

Final takeaways from ASCO 2021 and the use of immunotherapy to treat various types of patients with non–small cell lung cancer.

Blood-Based Biomarkers in NSCLC

August 25th 2021

The potential clinical utility of blood-based biomarkers in non–small cell lung cancer based on recent data presented at ASCO 2021.

Perioperative Approaches to NSCLC

August 25th 2021

Drs Chaitali Nangia and Sandip P. Patel debate between best treatment approaches for patients with non–small cell lung cancer in the perioperative setting.

Review of AENEAS Trial and Similar Agents

August 23rd 2021

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

EGFR-Targeted TKIs in NSCLC and Cost

August 23rd 2021

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

EGFR Mutation Heterogeneity

August 19th 2021

Recommendations for EGFR testing in patients with non–small cell lung cancer based on the wide heterogeneity of these mutations.

New Therapies for NSCLC With EGFR Exon 20 Insertions

August 19th 2021

Mark A. Socinski, MD, highlights the targeted agents available to treat non–small cell lung cancer with EGFR mutations.

Mobocertinib’s Safety Profile

August 19th 2021

Recommendations for mitigating and managing common treatment-related adverse events associated with mobocertinib and other tyrosine kinase inhibitors.

Biomarkers for Immunotherapy in Resectable NSCLC

August 18th 2021

Dr Roy S. Herbst comments on the utilization of biomarkers and information needed to help aid in treatment decisions about perioperative therapy for patients with resectable non–small cell lung cancer.

Atezolizumab After Adjuvant Chemotherapy in Resectable NSCLC

August 18th 2021

Dr Martin Dietrich comments on the IMpower010 trial of atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected non–small cell lung cancer.

Impact of Payers on the Costs of Drugs

August 16th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Personalized Therapies Based on Innovation and Affordability

August 16th 2021

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

EGFR Tyrosine Kinase Inhibitors and Brain Metastases

August 12th 2021

Commentary on the use of EGFR tyrosine kinase inhibitors and their efficacy on non–small cell lung cancer brain metastases.

EGFR Exon 20–Directed Therapy With Mobocertinib

August 12th 2021

Potential implications for treating patients with metastatic non–small cell lung cancers with EGFR exon 20 insertion mutations with mobocertinib, based on the EXCLAIM cohort.

Non–small Cell Lung Cancer With EGFR Exon 20 Insertion

August 12th 2021

Rare drivers such as EGFR exon 20 insertions and what they mean for treatment of patients with metastatic non–small cell lung cancer.

Targeted Therapy for Metastatic Non–small Cell Lung Cancer

August 12th 2021

Mark A. Socinski, MD shares a brief overview of the biomarkers and FDA-approved targeted therapies for non–small cell lung cancers.

Clinical Endpoints and Neoadjuvant Therapy for Resectable NSCLC

August 11th 2021

The impact of endpoints used in clinical trials of neoadjuvant therapy for resectable non–small cell lung cancer as they relate to newer drug approvals and real-world practice.

Neoadjuvant Immunotherapy for Resectable NSCLC

August 11th 2021

Martin Dietrich, MD, PhD, describes his interpretations of the KEYNOTE-799 study of pembrolizumab plus chemoradiation therapy for unresectable stage III non–small cell lung cancer.

Role of Financial Toxicity on Treatment Decisions

August 9th 2021

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

Definition of Financial Toxicity

August 9th 2021

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.